BC Week In Review | Aug 31, 2018
Company News

SEC charges ex-Sangamo exec with insider trading

The SEC charged Winson Tang, former VP of clinical research at Sangamo Therapeutics Inc. (NASDAQ:SGMO), and others with insider trading ahead of the biotech's 2014 licensing deal with Biogen Inc. (NASDAQ:BIIB). In a filing , the...
BioCentury | Apr 15, 2017
Finance

Formation focus

SV has tweaked the strategy for its sixth fund, focusing more of its biotech investment where it has made the best returns: in seed and series A investments. The firm also has diversified its LP...
BC Innovations | Dec 17, 2015
Strategy

San Diego ceiling

A decade ago, San Diego sat poised to compete with Boston and San Francisco as one of the nation's top biotech hubs, with Biocom , the local industry organization, making a priority of luring investors to...
BC Extra | Dec 9, 2015
Company News

FDA approves Bendeka for CLL, NHL

FDA approved Bendeka bendamustine RTD ( EP-3102 ) from Teva Pharmaceutical Industries Inc. (NYSE:TEVA) and Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) to treat chronic lymphocytic leukemia and indolent B cell non-Hodgkin's lymphoma that has progressed during or within six...
BC Week In Review | Aug 10, 2015
Company News

Syntonix, Biovitrum deal

Swedish Orphan Biovitrum AB (SSE:SOBI, Stockholm, Sweden) exercised an opt-in right from Biogen Inc. (NASDAQ:BIIB, Cambridge, Mass.) to take over development and commercialization of Alprolix in Europe, North Africa, Russia and 13 Middle Eastern countries....
BC Week In Review | May 11, 2015
Company News

Isis Pharmaceuticals, Biogen Idec deal

Isis received a $10 million milestone payment from Biogen under a 2013 deal under which the companies are using Isis’ antisense technology to identify and validate targets. The milestone was triggered by validation of an...
BC Extra | Mar 24, 2015
Company News

Biogen drops Idec from name

Biogen (NASDAQ:BIIB) changed its name from Biogen Idec Inc. The company had been called Biogen Idec since Biogen Inc. merged with Idec Pharmaceuticals Corp. in 2003. Biogen's shares fell $12.25 to $463.73 on Monday....
BC Week In Review | Mar 23, 2015
Clinical News

Aducanumab: Interim Phase Ib data

Interim data from 166 patients with prodromal or mild AD in the double-blind, dose-escalation, U.S. Phase Ib PRIME trial showed that 3, 6 and 10 mg/kg IV aducanumab significantly reduced mean levels of amyloid plaque,...
BC Week In Review | Mar 23, 2015
Clinical News

Gazyva obinutuzumab regulatory update

The U.K.’s NICE issued a final appraisal determination (FAD) recommending Gazyvaro obinutuzumab from Roche in combination with chlorambucil as first-line therapy for chronic lymphocytic leukemia (CLL) in patients who have comorbidities making them unsuitable for...
BC Week In Review | Mar 23, 2015
Company News

Biogen Idec, Eli Lilly, GlaxoSmithKline, J&J, Pfizer, Alzheimer’s Research UK, U.K. Department of Health neurology news

The U.K. government unveiled its $100 million Dementia Discovery Fund to support dementia research. GlaxoSmithKline invested $25 million, while Johnson & Johnson invested $10 million through its venture arm, Johnson & Johnson Innovation-JJDC Inc. Other...
Items per page:
1 - 10 of 3670
BC Week In Review | Aug 31, 2018
Company News

SEC charges ex-Sangamo exec with insider trading

The SEC charged Winson Tang, former VP of clinical research at Sangamo Therapeutics Inc. (NASDAQ:SGMO), and others with insider trading ahead of the biotech's 2014 licensing deal with Biogen Inc. (NASDAQ:BIIB). In a filing , the...
BioCentury | Apr 15, 2017
Finance

Formation focus

SV has tweaked the strategy for its sixth fund, focusing more of its biotech investment where it has made the best returns: in seed and series A investments. The firm also has diversified its LP...
BC Innovations | Dec 17, 2015
Strategy

San Diego ceiling

A decade ago, San Diego sat poised to compete with Boston and San Francisco as one of the nation's top biotech hubs, with Biocom , the local industry organization, making a priority of luring investors to...
BC Extra | Dec 9, 2015
Company News

FDA approves Bendeka for CLL, NHL

FDA approved Bendeka bendamustine RTD ( EP-3102 ) from Teva Pharmaceutical Industries Inc. (NYSE:TEVA) and Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) to treat chronic lymphocytic leukemia and indolent B cell non-Hodgkin's lymphoma that has progressed during or within six...
BC Week In Review | Aug 10, 2015
Company News

Syntonix, Biovitrum deal

Swedish Orphan Biovitrum AB (SSE:SOBI, Stockholm, Sweden) exercised an opt-in right from Biogen Inc. (NASDAQ:BIIB, Cambridge, Mass.) to take over development and commercialization of Alprolix in Europe, North Africa, Russia and 13 Middle Eastern countries....
BC Week In Review | May 11, 2015
Company News

Isis Pharmaceuticals, Biogen Idec deal

Isis received a $10 million milestone payment from Biogen under a 2013 deal under which the companies are using Isis’ antisense technology to identify and validate targets. The milestone was triggered by validation of an...
BC Extra | Mar 24, 2015
Company News

Biogen drops Idec from name

Biogen (NASDAQ:BIIB) changed its name from Biogen Idec Inc. The company had been called Biogen Idec since Biogen Inc. merged with Idec Pharmaceuticals Corp. in 2003. Biogen's shares fell $12.25 to $463.73 on Monday....
BC Week In Review | Mar 23, 2015
Clinical News

Aducanumab: Interim Phase Ib data

Interim data from 166 patients with prodromal or mild AD in the double-blind, dose-escalation, U.S. Phase Ib PRIME trial showed that 3, 6 and 10 mg/kg IV aducanumab significantly reduced mean levels of amyloid plaque,...
BC Week In Review | Mar 23, 2015
Clinical News

Gazyva obinutuzumab regulatory update

The U.K.’s NICE issued a final appraisal determination (FAD) recommending Gazyvaro obinutuzumab from Roche in combination with chlorambucil as first-line therapy for chronic lymphocytic leukemia (CLL) in patients who have comorbidities making them unsuitable for...
BC Week In Review | Mar 23, 2015
Company News

Biogen Idec, Eli Lilly, GlaxoSmithKline, J&J, Pfizer, Alzheimer’s Research UK, U.K. Department of Health neurology news

The U.K. government unveiled its $100 million Dementia Discovery Fund to support dementia research. GlaxoSmithKline invested $25 million, while Johnson & Johnson invested $10 million through its venture arm, Johnson & Johnson Innovation-JJDC Inc. Other...
Items per page:
1 - 10 of 3670